Overcoming Resistance
to Cancer Immunotherapy

Developing Novel Personalized Cancer Vaccines

We are a Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies. Our mission is to improve the lives of patients by developing novel therapies to overcome the underlying mechanisms by which tumor cells escape immune recognition.

About Us

Overcoming Two Major Obstacles that Limit the Effectiveness of Cancer Immunotherapies

We are advancing two proprietary technologies to overcome:

  • Primary or innate resistance related to tumor intrinsic factors associated with insufficient tumor immunogenicity; and
  • Secondary or acquired resistance to immunotherapies, resulting from extrinsic factors in the tissue in which the tumor lives (called the tumor microenvironment), which are separate from the biology of the tumor itself
Our Science

Targeting Multiple Cancers with Significant Unmet Need

Our approach enables us to target large unmet medical needs in a range of cancers, including Merkel Cell Carcinoma, B-Cell Malignancies, Myelodysplasia (Myelodysplastic Syndromes) and Acute Myeloid Leukemia.

Our Pipeline

Advancing Two Innovative Platform Technologies

Immune Fx (IFx) Personalized Cancer Vaccines

Our IFx technology is designed to activate the immune system to target and attack tumor cells by making tumor cells look like bacteria. Our approach provides a potent systemic response against all neoantigens in a patient’s tumor.

Learn More

Tumor Microenvironment Modulators

Our tumor microenvironment modulators are designed to address one of the primary causes of acquired resistance to immunotherapies, including checkpoint inhibitors or cellular therapies like CAR-T. Leveraging novel bi-functional antibody drug conjugates (ADCs), we are targeting a novel delta receptor on myeloid derived suppressor cells (MDSCs), which comprise 80% of cells in the tumor microenvironment and are responsible for suppressing the immune system’s attack against the tumor.

Learn More